Logo image of LLY

ELI LILLY & CO (LLY) Stock Fundamental Analysis

NYSE:LLY - New York Stock Exchange, Inc. - US5324571083 - Common Stock - Currency: USD

793.01  +2.36 (+0.3%)

After market: 793.01 0 (0%)

Fundamental Rating

6

LLY gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. While LLY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. LLY is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

LLY had positive earnings in the past year.
LLY had a positive operating cash flow in the past year.
LLY had positive earnings in each of the past 5 years.
LLY had a positive operating cash flow in each of the past 5 years.
LLY Yearly Net Income VS EBIT VS OCF VS FCFLLY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

1.2 Ratios

LLY has a Return On Assets of 12.42%. This is amongst the best in the industry. LLY outperforms 94.36% of its industry peers.
LLY's Return On Equity of 70.45% is amongst the best of the industry. LLY outperforms 98.46% of its industry peers.
LLY has a Return On Invested Capital of 27.17%. This is amongst the best in the industry. LLY outperforms 97.95% of its industry peers.
The Average Return On Invested Capital over the past 3 years for LLY is significantly above the industry average of 14.87%.
The last Return On Invested Capital (27.17%) for LLY is above the 3 year average (21.71%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.42%
ROE 70.45%
ROIC 27.17%
ROA(3y)11.42%
ROA(5y)11.8%
ROE(3y)60.64%
ROE(5y)70.77%
ROIC(3y)21.71%
ROIC(5y)19.96%
LLY Yearly ROA, ROE, ROICLLY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

With an excellent Profit Margin value of 22.66%, LLY belongs to the best of the industry, outperforming 94.87% of the companies in the same industry.
LLY's Profit Margin has declined in the last couple of years.
LLY has a better Operating Margin (40.25%) than 97.44% of its industry peers.
In the last couple of years the Operating Margin of LLY has grown nicely.
LLY's Gross Margin of 81.70% is amongst the best of the industry. LLY outperforms 87.18% of its industry peers.
LLY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 40.25%
PM (TTM) 22.66%
GM 81.7%
OM growth 3Y12.38%
OM growth 5Y7.84%
PM growth 3Y6.05%
PM growth 5Y-8.8%
GM growth 3Y3.11%
GM growth 5Y0.62%
LLY Yearly Profit, Operating, Gross MarginsLLY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so LLY is creating value.
LLY has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, LLY has less shares outstanding
The debt/assets ratio for LLY is higher compared to a year ago.
LLY Yearly Shares OutstandingLLY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
LLY Yearly Total Debt VS Total AssetsLLY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.2 Solvency

LLY has an Altman-Z score of 7.77. This indicates that LLY is financially healthy and has little risk of bankruptcy at the moment.
LLY's Altman-Z score of 7.77 is amongst the best of the industry. LLY outperforms 84.10% of its industry peers.
LLY has a Debt/Equity ratio of 2.19. This is a high value indicating a heavy dependency on external financing.
LLY has a worse Debt to Equity ratio (2.19) than 77.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.19
Debt/FCF N/A
Altman-Z 7.77
ROIC/WACC2.81
WACC9.67%
LLY Yearly LT Debt VS Equity VS FCFLLY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10B 20B

2.3 Liquidity

LLY has a Current Ratio of 1.37. This is a normal value and indicates that LLY is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.37, LLY is not doing good in the industry: 73.33% of the companies in the same industry are doing better.
A Quick Ratio of 1.06 indicates that LLY should not have too much problems paying its short term obligations.
The Quick ratio of LLY (1.06) is worse than 73.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.06
LLY Yearly Current Assets VS Current LiabilitesLLY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 89.01% over the past year.
LLY shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 16.57% yearly.
LLY shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.38%.
The Revenue has been growing by 15.08% on average over the past years. This is quite good.
EPS 1Y (TTM)89.01%
EPS 3Y16.75%
EPS 5Y16.57%
EPS Q2Q%29.46%
Revenue 1Y (TTM)36.38%
Revenue growth 3Y16.73%
Revenue growth 5Y15.08%
Sales Q2Q%45.17%

3.2 Future

LLY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.28% yearly.
The Revenue is expected to grow by 17.46% on average over the next years. This is quite good.
EPS Next Y67.5%
EPS Next 2Y50.52%
EPS Next 3Y41.49%
EPS Next 5Y30.28%
Revenue Next Year31.57%
Revenue Next 2Y25.34%
Revenue Next 3Y22.33%
Revenue Next 5Y17.46%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
LLY Yearly Revenue VS EstimatesLLY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B 100B
LLY Yearly EPS VS EstimatesLLY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20 40 60

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

LLY is valuated quite expensively with a Price/Earnings ratio of 57.63.
Compared to the rest of the industry, the Price/Earnings ratio of LLY indicates a somewhat cheap valuation: LLY is cheaper than 80.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.47, LLY is valued quite expensively.
The Price/Forward Earnings ratio is 26.92, which means the current valuation is very expensive for LLY.
LLY's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. LLY is cheaper than 70.26% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.91, LLY is valued a bit more expensive.
Industry RankSector Rank
PE 57.63
Fwd PE 26.92
LLY Price Earnings VS Forward Price EarningsLLY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

78.97% of the companies in the same industry are more expensive than LLY, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 36.4
LLY Per share dataLLY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
LLY has an outstanding profitability rating, which may justify a higher PE ratio.
LLY's earnings are expected to grow with 41.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.85
PEG (5Y)3.48
EPS Next 2Y50.52%
EPS Next 3Y41.49%

More info and screens

6

5. Dividend

5.1 Amount

With a yearly dividend of 0.77%, LLY is not a good candidate for dividend investing.
LLY's Dividend Yield is rather good when compared to the industry average which is at 4.05. LLY pays more dividend than 89.74% of the companies in the same industry.
With a Dividend Yield of 0.77, LLY pays less dividend than the S&P500 average, which is at 2.37.
Industry RankSector Rank
Dividend Yield 0.77%

5.2 History

On average, the dividend of LLY grows each year by 15.60%, which is quite nice.
LLY has been paying a dividend for at least 10 years, so it has a reliable track record.
LLY has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)15.6%
Div Incr Years10
Div Non Decr Years34
LLY Yearly Dividends per shareLLY Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3 4 5

5.3 Sustainability

43.74% of the earnings are spent on dividend by LLY. This is a bit on the high side, but may be sustainable.
The dividend of LLY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP43.74%
EPS Next 2Y50.52%
EPS Next 3Y41.49%
LLY Yearly Income VS Free CF VS DividendLLY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B 6B 8B 10B
LLY Dividend Payout.LLY Dividend Payout, showing the Payout Ratio.LLY Dividend Payout.PayoutRetained Earnings

More info and screens

ELI LILLY & CO

NYSE:LLY (7/11/2025, 4:07:50 PM)

After market: 793.01 0 (0%)

793.01

+2.36 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners83.95%
Inst Owner Change0.02%
Ins Owners0.16%
Ins Owner Change-0.74%
Market Cap751.57B
Analysts81.21
Price Target987.06 (24.47%)
Short Float %0.85%
Short Ratio1.93
Dividend
Industry RankSector Rank
Dividend Yield 0.77%
Yearly Dividend4.93
Dividend Growth(5Y)15.6%
DP43.74%
Div Incr Years10
Div Non Decr Years34
Ex-Date08-15 2025-08-15 (1.5)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.92%
Min EPS beat(2)6.45%
Max EPS beat(2)9.38%
EPS beat(4)3
Avg EPS beat(4)11.23%
Min EPS beat(4)-20.34%
Max EPS beat(4)49.43%
EPS beat(8)7
Avg EPS beat(8)29.89%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)11
Avg EPS beat(16)14.81%
Revenue beat(2)0
Avg Revenue beat(2)-0.87%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.5%
Revenue beat(4)1
Avg Revenue beat(4)1.15%
Min Revenue beat(4)-6.46%
Max Revenue beat(4)12.82%
Revenue beat(8)4
Avg Revenue beat(8)2.39%
Revenue beat(12)5
Avg Revenue beat(12)0.98%
Revenue beat(16)9
Avg Revenue beat(16)1.3%
PT rev (1m)-2.61%
PT rev (3m)-5.38%
EPS NQ rev (1m)0.25%
EPS NQ rev (3m)1.02%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)-6.97%
Revenue NQ rev (1m)0.24%
Revenue NQ rev (3m)0.86%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.31%
Valuation
Industry RankSector Rank
PE 57.63
Fwd PE 26.92
P/S 15.34
P/FCF N/A
P/OCF 80.66
P/B 47.67
P/tB 188.74
EV/EBITDA 36.4
EPS(TTM)13.76
EY1.74%
EPS(NY)29.45
Fwd EY3.71%
FCF(TTM)-1.34
FCFYN/A
OCF(TTM)9.83
OCFY1.24%
SpS51.71
BVpS16.63
TBVpS4.2
PEG (NY)0.85
PEG (5Y)3.48
Profitability
Industry RankSector Rank
ROA 12.42%
ROE 70.45%
ROCE 33.25%
ROIC 27.17%
ROICexc 28.73%
ROICexgc 36.37%
OM 40.25%
PM (TTM) 22.66%
GM 81.7%
FCFM N/A
ROA(3y)11.42%
ROA(5y)11.8%
ROE(3y)60.64%
ROE(5y)70.77%
ROIC(3y)21.71%
ROIC(5y)19.96%
ROICexc(3y)23.23%
ROICexc(5y)21.74%
ROICexgc(3y)32.89%
ROICexgc(5y)32.31%
ROCE(3y)29.19%
ROCE(5y)26%
ROICexcg growth 3Y1.59%
ROICexcg growth 5Y4.02%
ROICexc growth 3Y9.55%
ROICexc growth 5Y8.81%
OM growth 3Y12.38%
OM growth 5Y7.84%
PM growth 3Y6.05%
PM growth 5Y-8.8%
GM growth 3Y3.11%
GM growth 5Y0.62%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 2.19
Debt/FCF N/A
Debt/EBITDA 1.6
Cap/Depr 578.92%
Cap/Sales 21.61%
Interest Coverage 250
Cash Conversion 43.23%
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.06
Altman-Z 7.77
F-Score6
WACC9.67%
ROIC/WACC2.81
Cap/Depr(3y)374.28%
Cap/Depr(5y)279.43%
Cap/Sales(3y)16.34%
Cap/Sales(5y)12.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.01%
EPS 3Y16.75%
EPS 5Y16.57%
EPS Q2Q%29.46%
EPS Next Y67.5%
EPS Next 2Y50.52%
EPS Next 3Y41.49%
EPS Next 5Y30.28%
Revenue 1Y (TTM)36.38%
Revenue growth 3Y16.73%
Revenue growth 5Y15.08%
Sales Q2Q%45.17%
Revenue Next Year31.57%
Revenue Next 2Y25.34%
Revenue Next 3Y22.33%
Revenue Next 5Y17.46%
EBIT growth 1Y73.83%
EBIT growth 3Y31.18%
EBIT growth 5Y24.1%
EBIT Next Year83.18%
EBIT Next 3Y42.52%
EBIT Next 5Y29.3%
FCF growth 1Y-133.54%
FCF growth 3Y-57.48%
FCF growth 5Y-34.68%
OCF growth 1Y36.68%
OCF growth 3Y6.69%
OCF growth 5Y12.76%